UPDATE: Bioclinica, Inc. (BIOC) Reports Inline Q1 EPS of 8c; Guides to High End for FY12
Tweet
Share
E-mailGet Alerts BIOC Hot Sheet
Join SI Premium – FREE
(Updated - May 9, 2012 3:03 PM EDT)
Bioclinica, Inc. (NASDAQ: BIOC) reported Q1 EPS of $0.08, inline with the analyst estimate of $0.08. Revenue for the quarter came in at $22.69 million versus the consensus estimate of $18.4 million.
Bioclinica, Inc. sees FY2012 EPS of $0.36-$0.42 vs. consensus of $0.36. Reiterating expectations for full-year 2012 service revenue to be in the range of $73 to $77 million.
For earnings history and earnings-related data on Bioclinica, Inc. (BIOC) click here.
Bioclinica, Inc. (NASDAQ: BIOC) reported Q1 EPS of $0.08, inline with the analyst estimate of $0.08. Revenue for the quarter came in at $22.69 million versus the consensus estimate of $18.4 million.
Bioclinica, Inc. sees FY2012 EPS of $0.36-$0.42 vs. consensus of $0.36. Reiterating expectations for full-year 2012 service revenue to be in the range of $73 to $77 million.
For earnings history and earnings-related data on Bioclinica, Inc. (BIOC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fox upgraded to overweight as Roku deal, ad strength lift outlook
- Star Equity Holdings (STRR) Misses Q2 EPS by 8c
- U.S. equity funds draw inflows as rate-hike concerns ease
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
